The efficacy of Anrotinib is to inhibit tumor angiogenesis and reduce the blood supply of tumor blood vessels, so as to inhibit the proliferation and spread of tumor cells. Anrotinib is a novel anti-angiogenic targeted drug that mainly acts on platelet-derived growth factor receptors and receptors for vascular endothelial cell growth factor. It has therapeutic effects on malignant tumors such as non-small cell lung cancer, adenovascular soft tissue sarcoma, and clear cell sarcoma. Due to individual variability, adverse reactions such as dizziness, nausea and vomiting can occur during the use of Anrotinib, and it is contraindicated for patients who are allergic to the drug. The drug needs to be used under the guidance of a doctor, do not use the drug blindly. It is recommended to receive standardized treatment under the guidance of a doctor in conjunction with their own situation, and to consult a doctor in a timely manner when adverse reactions occur.